Stockreport

Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question [Seeking Alpha]

Annovis Bio, Inc.  (ANVS) 
PDF The exclusion of 37% of the patient population and the focus on mild AD patients were not pre-specified, raising concerns. Annovis faces financial challenges and may [Read more]